PRODUCT LAUNCH

Ground-Breaking Test for Evaluating Growth and Survival of CAR-T Therapy in Cancer Patients

A revolutionary test that can measure the progression and durability of Chimeric Antigen Receptor T-Cell (CAR-T) treatment in patients with pre-B cell acute lymphoblastic leukaemia and B cell lymphomas has been made available, according to Eurofins Viracor LLC.

The test is made to make it easier for clinicians to comprehend how CAR-T therapy is working for their patients.

CAR-T therapy is a cutting-edge type of immunotherapy that uses genetically modified T-cells to target cancer cells and has demonstrated promising outcomes in the treatment of a number of cancers.

The test is intended to give clinicians a precise and thorough evaluation of the CAR-T cell population in the patient's body and may provide information about the efficacy of the therapy

The launch of this test represents a significant advancement in the assessment and administration of CAR-T treatment for cancer patients.

It is anticipated to be a useful tool for assisting clinicians in selecting the most appropriate course of therapy for their patients.

Partnership

Memora Health Partners with Moffitt Cancer Center to Scale Data-Driven Cancer Care

Read the complete post

Memora Health and Moffitt Cancer Center have announced a partnership to scale data-driven cancer care.

The groundbreaking collaboration will combine Moffitt's oncology expertise with Memora's clinical intelligence care platform to enhance the patient experience and give Moffitt's clinicians and provider’s direct access to the platform in order to meet urgent patient requirements.

Clinicians all over the world frequently use Moffitt's clinical insights to inform treatment choices for patients getting oncology care. However, these clinical insights have not been used to directly engage with patients in a manner that would allow them to be educated, adhere to their treatment regimens, and be monitored for symptoms specific to their diagnosis.

By automating care journeys, Memora's platform makes complicated care delivery for patients and their providers simpler. The programme offers patients constant two-way contact about their care and intelligently assigns patient questions and clinical concerns to the best members of the care team.

Fda Approval

Eko Launches SENSORA™ Cardiac Disease Detection Platform

Eko has announced the launch of the SENSORA™ Cardiac Disease Monitoring Platform.

The current version of SENSORA™ includes both AI and Care Pathway Analytics software, which objectively identifies structural murmurs, a sign of valvular heart disease, and provides downstream visibility and metrics of the patient journey through the healthcare system.

The stethoscope, one of the most widely used medical instruments in the world, is combined with the most recent developments in applied machine learning to create the cardiovascular disease detection tool known as SENSORA™.

Eko has invented a detection tool that will grow as the company develops apps for more cardiac conditions by using its digital stethoscopes to record and analyze electrical signals and heart sounds.

During a routine visit with their primary care physician, patients with valvular heart disease (VHD) can be more reliably and accurately diagnosed with valvular heart disease (VHD) with the SENSORA™ FDA-cleared structural murmur detection.

The company's current portfolio includes five FDA 510(k) cleared digital solutions in addition to two machine learning algorithms, named ELEFT and EKO, being developed to detect pulmonary hypertension in addition to its software that detects a weak heart pump.

Product Launch

Bruker introduces new SKYSCAN™ 2214 CMOS Edition Nanoscale 3D X-ray Microscope

A multiscale X-ray microscope built on nanoCT (computed tomography) for commercial and academic research was unveiled by Bruker as the SKYSCAN™ 2214 CMOS Edition.

The highly effective and proven SKYSCAN 2214 platform now includes the most recent scientific CMOS (sCMOS) detector technology, taking highresolution X-ray imaging to a new level.

The cutting-edge modular design of the SKYSCAN 2214 CMOS accommodates up to four detectors for your samples and uses. It's new 6MP flat screen and three enhanced 15/16MP sCMOS detectors have the largest field of vision for true 3D resolution down to the 500n range.

Due to their extensive dynamic range and exceptionally low noise, the new sCMOS detectors also shine at imaging high- and low-density features in the same object.

The SKYSCAN 2214 CMOS Edition is enhanced by the user-friendly 3D.SUITE software, which allows for simple data gathering, sophisticated image analysis, and potent visualization. Advanced features like spiral scanning and variable rotation step tomography are part of this potent software package.

Furthermore, features that would normally be hidden when using only absorption contrast imaging can be seen when using phase retrieval algorithms for propagation-based phase contrast X-ray imaging.

The minimal maintenance requirements of SKYSCAN 2214 CMOS Edition increase system uptime and lower total cost of ownership.